FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560692010> ?p ?o ?g. }

• W2560692010 endingPage "438" @default.
• W2560692010 startingPage "425" @default.
• W2560692010 abstract "The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim (6- and 11-day), to reduce the incidence of febrile neutropenia (FN) in patients with stage II breast cancer receiving TC (docetaxel, cyclophosphamide) and in patients with non-Hodgkin lymphoma (NHL) receiving R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) over a lifetime horizon from a Belgian payer perspective.A Markov cycle tree tracked FN events during chemotherapy (3-week cycles) and long-term survival (1-year cycles). Model inputs, including the efficacy of each strategy, risk of reduced relative dose intensity (RDI), and the impact of RDI on mortality, utilities, and costs (in €; 2014 values) were estimated from public sources and the published literature. Incremental cost-effectiveness ratios (ICERs) were assessed for each strategy for costs per FN event avoided, life-year (LY) saved, and quality-adjusted LY (QALY) saved. LYs and QALYs saved were discounted at 1.5% annually. Deterministic and probabilistic sensitivity analyses (DSAs and PSAs) were conducted.Base-case ICERs for PP with pegfilgrastim relative to SP with pegfilgrastim were €15,500 per QALY and €14,800 per LY saved for stage II breast cancer and €7800 per QALY and €6900 per LY saved for NHL; other comparators were either more expensive and less effective than PP or SP with pegfilgrastim or had lower costs but higher ICERs (relative to SP with pegfilgrastim) than PP with pegfilgrastim. Results of the DSA for breast cancer and NHL comparing PP and SP with pegfilgrastim indicate that the model results were most sensitive to the cycle 1 risk of FN, the proportion of FN events requiring hospitalization, the relative risk of FN in cycles ≥2 versus cycle 1, no history of FN, and the mortality hazard ratio for RDI (<90% vs ≥90% [for NHL]). In the PSAs for stage II breast cancer and NHL, the probabilities that PP with pegfilgrastim was cost effective or dominant versus all other prophylaxis strategies at a €30,000/QALY willingness-to-pay threshold were 52% (other strategies ≤24%) and 58% (other strategies ≤24%), respectively.From a Belgian payer perspective, PP with pegfilgrastim appears cost effective compared to other prophylaxis strategies in patients with stage II breast cancer or NHL at a €30,000/QALY threshold." @default.
• W2560692010 created "2016-12-16" @default.
• W2560692010 creator A5031997572 @default.
• W2560692010 creator A5041311712 @default.
• W2560692010 creator A5048529874 @default.
• W2560692010 creator A5049711046 @default.
• W2560692010 creator A5054110969 @default.
• W2560692010 creator A5073060840 @default.
• W2560692010 creator A5076341878 @default.
• W2560692010 creator A5085388820 @default.
• W2560692010 creator A5087881007 @default.
• W2560692010 creator A5089079624 @default.
• W2560692010 date "2016-12-07" @default.
• W2560692010 modified "2023-10-02" @default.
• W2560692010 title "Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma" @default.
• W2560692010 cites W1858470829 @default.
• W2560692010 cites W1944652052 @default.
• W2560692010 cites W194795933 @default.
• W2560692010 cites W1969840975 @default.
• W2560692010 cites W1971078174 @default.
• W2560692010 cites W1973935677 @default.
• W2560692010 cites W1978906303 @default.
• W2560692010 cites W1983905226 @default.
• W2560692010 cites W1989925579 @default.
• W2560692010 cites W1990248717 @default.
• W2560692010 cites W2000900335 @default.
• W2560692010 cites W2001778629 @default.
• W2560692010 cites W2002413147 @default.
• W2560692010 cites W2009475216 @default.
• W2560692010 cites W2013754529 @default.
• W2560692010 cites W2014382998 @default.
• W2560692010 cites W2016751107 @default.
• W2560692010 cites W2020677481 @default.
• W2560692010 cites W2035811581 @default.
• W2560692010 cites W2043790030 @default.
• W2560692010 cites W2048687800 @default.
• W2560692010 cites W2058294694 @default.
• W2560692010 cites W2059070026 @default.
• W2560692010 cites W2069191600 @default.
• W2560692010 cites W2071941963 @default.
• W2560692010 cites W2076143652 @default.
• W2560692010 cites W2077781144 @default.
• W2560692010 cites W2077962461 @default.
• W2560692010 cites W2083336892 @default.
• W2560692010 cites W2100082529 @default.
• W2560692010 cites W2110534467 @default.
• W2560692010 cites W2115170812 @default.
• W2560692010 cites W2121218075 @default.
• W2560692010 cites W2133120925 @default.
• W2560692010 cites W2137717503 @default.
• W2560692010 cites W2150883028 @default.
• W2560692010 cites W2155817335 @default.
• W2560692010 cites W2157799421 @default.
• W2560692010 cites W2169403306 @default.
• W2560692010 cites W2170833511 @default.
• W2560692010 cites W2404992808 @default.
• W2560692010 doi "https://doi.org/10.1007/s40273-016-0474-0" @default.
• W2560692010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5357483" @default.
• W2560692010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27928760" @default.
• W2560692010 hasPublicationYear "2016" @default.
• W2560692010 type Work @default.
• W2560692010 sameAs 2560692010 @default.
• W2560692010 citedByCount "25" @default.
• W2560692010 countsByYear W25606920102017 @default.
• W2560692010 countsByYear W25606920102018 @default.
• W2560692010 countsByYear W25606920102019 @default.
• W2560692010 countsByYear W25606920102020 @default.
• W2560692010 countsByYear W25606920102021 @default.
• W2560692010 countsByYear W25606920102022 @default.
• W2560692010 countsByYear W25606920102023 @default.
• W2560692010 crossrefType "journal-article" @default.
• W2560692010 hasAuthorship W2560692010A5031997572 @default.
• W2560692010 hasAuthorship W2560692010A5041311712 @default.
• W2560692010 hasAuthorship W2560692010A5048529874 @default.
• W2560692010 hasAuthorship W2560692010A5049711046 @default.
• W2560692010 hasAuthorship W2560692010A5054110969 @default.
• W2560692010 hasAuthorship W2560692010A5073060840 @default.
• W2560692010 hasAuthorship W2560692010A5076341878 @default.
• W2560692010 hasAuthorship W2560692010A5085388820 @default.
• W2560692010 hasAuthorship W2560692010A5087881007 @default.
• W2560692010 hasAuthorship W2560692010A5089079624 @default.
• W2560692010 hasBestOaLocation W25606920101 @default.
• W2560692010 hasConcept C112930515 @default.
• W2560692010 hasConcept C121608353 @default.
• W2560692010 hasConcept C126322002 @default.
• W2560692010 hasConcept C141071460 @default.
• W2560692010 hasConcept C143998085 @default.
• W2560692010 hasConcept C2776694085 @default.
• W2560692010 hasConcept C2777063308 @default.
• W2560692010 hasConcept C2778658803 @default.
• W2560692010 hasConcept C2778850193 @default.
• W2560692010 hasConcept C2779338263 @default.
• W2560692010 hasConcept C2779725641 @default.
• W2560692010 hasConcept C3019080777 @default.
• W2560692010 hasConcept C530470458 @default.
• W2560692010 hasConcept C71924100 @default.
• W2560692010 hasConceptScore W2560692010C112930515 @default.
• W2560692010 hasConceptScore W2560692010C121608353 @default.

• next